iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Team
Lead product candidate, ITOL-101, for the treatment of Type 1 Diabetes entering IND-enabling studies
Anthony Japour, M.D., a seasonedbiotech and pharmaceutical executive with over 30 years of experience, appointed as Chief Executive Officer
Camillo Ricordi, M.D., one of the world s leading scientists in diabetes cure-focused research, cell transplantation and regenerative medicine, appointed as Chief Scientist
SAN MATEO, CA / ACCESSWIRE / June 9, 2021 / iTolerance, Inc
. ( iTolerance or the Company ), a biotechnology company focused on the development of innovative regenerative medicines, today announced the formation of its Executive Leadership Team with the hiring of Anthony Japour, M.D. as Chief Executive Officer and Camillo Ricordi, M.D. as Chief Scientist.
(2)
NEW YORK CITY (dpa-AFX) - Today s Daily Dose brings you news about BNT162b2 vaccine s capability to neutralize the new UK coronavirus variant, the resignation of Stephen Hahn, the 24th Commissioner of the FDA, the executive changes at Lineage Cell Therapeutics and registered offering of OncoCyte.
Read on.
1. Lineage Cell s CFO Resigns
Lineage Cell Therapeutics Inc. s (LCTX) Chief Financial Officer, Brandi Roberts, has resigned in order to accept a leadership position at another company.
The CEO of Lineage Cell, Brian Culley, will serve as Interim Chief Financial Officer. Meanwhile, the company has initiated a search for a new CFO.